Safety and Efficacy of Ibutilide in Cardioversion of Atrial Flutter and Fibrillation

References

1. ↵
   Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–33.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Mazzocca G, Corbucci G, Venturini E, Becuzzi L. Is pretreatment with ibutilide useful for atrial fibrillation cardioversion when combined with biphasic shock? J Cardiovasc Med 2006; 7: 124–8.

   OpenUrl
3. ↵
   Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with Ibutilide pretreatment. N Engl J Med 1999; 340: 1849–54.

   OpenUrlCrossRefPubMedWeb of Science
4. Oral H, Knight BP, Sticherling C, et al. Cost analysis of transthoracic cardioversion of atrial fibrillation with and without ibutilide pretreatment. J Cardiovasc Pharmacol Ther 2000; 5: 259–66.

   OpenUrlAbstract/FREE Full Text
5. ↵
   European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854–906.

   OpenUrl
6. ↵
   Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001; 104: 1933–9.

   OpenUrlAbstract/FREE Full Text
7. ↵
   Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993; 22: 540–9.

   OpenUrlPubMedWeb of Science
8. ↵
   Kowey PR, VanderLugt JT, Luderer JT. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78(Suppl 8A): 46–52.

   OpenUrlCrossRefPubMed
9. ↵
   Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996; 78: 12–6.

   OpenUrlPubMedWeb of Science
10. ↵
    Stambler BS, Beckham KJ, Kadish AH, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997; 80: 458–63.

    OpenUrlCrossRefPubMed
11. ↵
    Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94: 1613–21.

    OpenUrlAbstract/FREE Full Text
12. ↵
    Vos MA, Golitsyn SR, Stangi K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/ Sotalol Comparator Study Group. Heart 1998; 79: 568–75.

    OpenUrlAbstract/FREE Full Text
13. ↵
    Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31: 1414–9.

    OpenUrlCrossRefPubMedWeb of Science
14. Stambler BS, Wood AM, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96: 4298–306.

    OpenUrlAbstract/FREE Full Text
15. ↵
    Pinter A, Dorian P. Intravenous antiarrhythmic agents. Curr Opin Cardiol 2001; 16: 17–22.

    OpenUrlCrossRefPubMed
16. ↵
    Kafkas NV, Patsilinakos SP, Mertzanos GA, et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol 2007; 118: 321–5.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Ando G, Di Rosa S, Rizzo F, et al. Ibutilide for cardioversion of atrial flutter: efficacy of a single dose in recent-onset arrhythmias. Minerva Cardioangiol 2004; 52: 37–42.

    OpenUrlPubMed
18. ↵
    Reisinger J, Gatterer E, Lang W, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004; 25: 1318–24.

    OpenUrlAbstract/FREE Full Text
19. ↵
    VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100: 369–75.

    OpenUrlAbstract/FREE Full Text
20. ↵
    Bernard EO, Schmid ER, Schmidlin D, Scharf C, Candinas R, Germann R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med 2003; 31: 1031–4.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Soucier R, Silverman D, Abordo M, et al. Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study). Med Sci Monit 2003; 9: PI19–23.

    OpenUrlPubMed
22. ↵
    Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with Ibutilide in patients receiving amiodarone therapy. Circulation 2001; 103: 253–7.

    OpenUrlAbstract/FREE Full Text
23. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 89: 239–48.

    OpenUrlCrossRefPubMedWeb of Science
24. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861–72.

    OpenUrlCrossRefPubMedWeb of Science
25. Zehender M, Hohnloser S, Muller B, et al. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19: 1054–9.

    OpenUrlPubMedWeb of Science
26. Tieleman RG, Gosselink AT, Crijns HJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79: 53–7.

    OpenUrlCrossRefPubMedWeb of Science
27. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999; 33: 966–71.

    OpenUrlCrossRefPubMedWeb of Science
28. Galperin J, Elizari MV, Chiale PA, et al. Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. J Cardiovasc Pharmacol Ther 2003; 8: 179–86.

    OpenUrlAbstract/FREE Full Text
29. Galperin J, Elizari MV, Chaile PA, et al. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther 2001; 6: 341–50.

    OpenUrlAbstract/FREE Full Text
30. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37: 542–7.

    OpenUrlCrossRefPubMedWeb of Science
31. Rodriguez EV, Rodriguez CC, Estrada SA, Rojo JR, Morales EH, Munoz AU. Pharmacological cardioversion with intravenous propafenone in atrial fibrillation. Arch Inst Cardiol Mex 2000; 70: 160–6.

    OpenUrlPubMed
32. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, Chlouverakis GI, Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of randomized, controlled study. J Am Coll Cardiol 1999; 33: 966–71.

    OpenUrlCrossRefPubMedWeb of Science
33. Suttorp MJ, Kingma JH, Jessurun ER, Lie AH, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722–7.

    OpenUrlPubMedWeb of Science
34. Fenster PE, Comess KA, Marsh R, et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501–4.

    OpenUrlCrossRefPubMedWeb of Science
35. Abi-Mansour P, Carberry PA, Mc Cowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter or atrial fibrillation. Am Heart J 1998; 136: 632–42.

    OpenUrlCrossRefPubMedWeb of Science
36. Simpson CS, Yee R, Lee JK, et al. Safety and feasibility of a novel rate-smoothed ventricular pacing algorithm for atrial fibrillation. Am Heart J 2001; 142: 294–300.

    OpenUrlCrossRefPubMedWeb of Science
37. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29: 385–90.

    OpenUrlCrossRefPubMedWeb of Science
38. Cotiga D, Arshad A, Aziz E, Joshi S, Koneru JN, Steinberg JS. Acute conversion of persistent atrial fibrillation during dofetilide initiation. Pacing Clin Electrophysiol 2007; 30: 1527–30.

    OpenUrlPubMed
39. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385–90.

    OpenUrlAbstract/FREE Full Text
40. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 87: 121–8.

    OpenUrlCrossRefPubMedWeb of Science
41. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992; 70: 56A–60A.

    OpenUrlCrossRefPubMed
42. ↵
    Zaqqa M, Afshar H, Rasekh A, Khoshnevis R, Vaughn WK, Massumi A. Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter. Am J Cardiol 2000; 85: 112–4.

    OpenUrlCrossRefPubMedWeb of Science
43. ↵
    Cheng J, Glatter K, Yang Y, Zhang S, Lee R, Scheinman MM. Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation 2002; 106: 814–9.

    OpenUrlAbstract/FREE Full Text
44. ↵
    Guo GH, Ellenbogen KA, Wood MA, et al. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996; 27: 1083–9.

    OpenUrlCrossRefPubMedWeb of Science
45. ↵
    Tai CT, Chen SA, Feng AN, Yu WC, Chen YJ, Chang MS. Electrophysiologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Circulation 1998; 97: 1935–45.

    OpenUrlAbstract/FREE Full Text
46. ↵
    Stambler BS, Wood AM, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by overdrive pacing. Am J Cardiol 1996; 77: 960–6.

    OpenUrlCrossRefPubMedWeb of Science
47. ↵
    Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol 2007; 30: 1003–8.

    OpenUrlCrossRefPubMed
48. ↵
    Gowda RM, Khan IA, Punukollu G, et al. Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly. Am J Ther 2004; 11: 95–7.

    OpenUrlPubMed
49. ↵
    Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S. Classification and mechanism of torsade de pointes initiation in patients with congenital long QT syndrome. Eur Heart J 2004; 25: 2149–54.

    OpenUrlAbstract/FREE Full Text
50. ↵
    Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: the clinical considerations. Int J Cardiol 2004; 96: 1–6.

    OpenUrlCrossRefPubMedWeb of Science
51. ↵
    Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res 1993; 27: 2186–93.

    OpenUrlAbstract/FREE Full Text
52. ↵
    Gowda RM, Khan IA, Punukollu G, et al. Female preponderance in ibutilide induced torsade de pointes. Int J Cardiol 2004; 95: 219–22.

    OpenUrlCrossRefPubMedWeb of Science
53. ↵
    Chiladakis JA, Kalogeropoulos A, Patsouras N, et al. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol 2004; 44: 859–63.

    OpenUrlCrossRefPubMedWeb of Science
54. ↵
    Hongo RH, Themistoclakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004; 44: 864–8.

    OpenUrlCrossRefPubMedWeb of Science
55. ↵
    Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106: 673–6.

    OpenUrlCrossRefPubMed
56. ↵
    Steinwender C, Hönig S, Kypta A, et al. Preinjection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter. Int J Cardiol 2010; 141: 260–5.

    OpenUrlPubMed